Drug Profile
Research programme: chemokine receptor antagonists - Ipsen/University of Cambridge
Latest Information Update: 15 Oct 2007
Price :
$50
*
At a glance
- Originator University of Cambridge
- Developer Ipsen; University of Cambridge
- Class
- Mechanism of Action Chemokine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 30 Aug 2004 No development reported - Preclinical for Inflammation in United Kingdom (unspecified route)
- 05 Jun 2003 Beaufour-Ipsen is now called Ipsen
- 13 Mar 2002 Preclinical trials in Inflammation in United Kingdom (unspecified route)